Latest report
World
Preview 2016
The latest edition of World Preview 2016 is now
available to download, providing a snapshot of the
industry in 2016. EvaluatePharma's consensus forecasts
now extend to 2016 and this is the first time this data has been
available, giving you exclusive insights into the new competitive
pharma landscape beyond the patent cliff.
Analysis highlights include:
- Worldwide prescription drug
sales total $785bn in 2016 with 2.9% (CAGR) 2009-2016
- Humira World's largest selling
product in 2016
- Over $267bn of sales at risk
from patent expirations in 2011-16
- Teva within Top 10 drug companies
by 2016
- Pfizer Maintains Top Spot in
2016 via Wyeth Acquisition
- Global pharmaceutical R&D
spend to grow by 2.3% (CAGR) to $145bn by 2016
- Biotech products fail to
overtake small molecule within Top 100 Drugs by 2016
- Anti-coagulants set to record
highest growth of major therapy categories to 2016
- Sales potential of 2009 new
drugs (NMEs) up 34% vs. 2008 cohort of
NME
Download
World Preview 2016 for
a review of forecasted trends in prescription drug sales, R&D
spend, therapy area growth and the performance of marketed and pipeline
products. |
